secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000950170-23-000495
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta prelim Q4 revenue $235.5M, FY $843.3M, exceeding guidance
-----------------------------------------------------------------

- Preliminary Q4 2022 net product revenue ~$235.5M, up 32% YoY.
- Full-year 2022 net product revenue ~$843.3M, up 38% YoY, exceeding guidance of $825-840M.
- Year-end cash balance ~$2.0B, down slightly from $2.1B at end of 2021.
- Revenues from three RNA-based PMO therapies: EXONDYS 51, VYONDYS 53, AMONDYS 45.
- Final Q4/FY results expected in late February 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000095017023000495/0000950170-23-000495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000095017023000495/srpt-20230109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer